Cancer drug go-ahead

THOUSANDS of cancer patients will be eligible for an “effective and valuable” treatment after it was recommended by a health watchdog.

Some 8,000 people in England with hormonesensitive or hormone-relapsed prostate cancer will now be eligible for treatment with apalutamide.

The recommendation comes after a discount was agreed for the drug, also called Erleada and made by pharmaceutical giant Janssen, to be available on the NHS.